Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Götte

Showing results (1-10 of 123) with videos related to

Pageof 13
Sort By:
Current Opinion in Virology|September 12, 2012
The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistanceMatthias Götte
Plos Medicine|December 7, 2007
Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testingMatthias Götte
Current Opinion in HIV and AIDS|April 18, 2009
Mechanisms of resistance associated with excision of incorporated nucleotide analogue inhibitors of HIV-1 reverse transcriptaseMatthias Götte
Expert Review of Anti-Infective Therapy|October 16, 2004
Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistanceMatthias Götte
Current Opinion in Virology|August 18, 2014
Resistance to nucleotide analogue inhibitors of hepatitis C virus NS5B: mechanisms and clinical relevanceMatthias Götte
Viruses|October 14, 2011
Initiation of HIV reverse transcription: is enzyme flipping required?Matthias Götte
Current Pharmaceutical Design|May 27, 2006
Effects of nucleotides and nucleotide analogue inhibitors of HIV-1 reverse transcriptase in a ratchet model of polymerase translocationMatthias Götte
Current Opinion in Virology|May 30, 2021
Remdesivir for the treatment of Covid-19: the value of biochemical studiesMatthias Götte
Viruses|January 10, 2013
Utility of the bacteriophage RB69 polymerase gp43 as a surrogate enzyme for herpesvirus orthologsNicholas Bennett, Matthias Götte
AIDS Reviews|December 19, 2008
Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibilityMaryam Ehteshami, Matthias Götte
Pageof 13

Showing results (1-10 of 123) with videos related to

Sort By:
Pageof 13
Current Opinion in Virology|September 12, 2012
The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistanceMatthias Götte
Plos Medicine|December 7, 2007
Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testingMatthias Götte
Current Opinion in HIV and AIDS|April 18, 2009
Mechanisms of resistance associated with excision of incorporated nucleotide analogue inhibitors of HIV-1 reverse transcriptaseMatthias Götte
Expert Review of Anti-Infective Therapy|October 16, 2004
Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistanceMatthias Götte
Current Opinion in Virology|August 18, 2014
Resistance to nucleotide analogue inhibitors of hepatitis C virus NS5B: mechanisms and clinical relevanceMatthias Götte
Viruses|October 14, 2011
Initiation of HIV reverse transcription: is enzyme flipping required?Matthias Götte
Current Pharmaceutical Design|May 27, 2006
Effects of nucleotides and nucleotide analogue inhibitors of HIV-1 reverse transcriptase in a ratchet model of polymerase translocationMatthias Götte
Current Opinion in Virology|May 30, 2021
Remdesivir for the treatment of Covid-19: the value of biochemical studiesMatthias Götte
Viruses|January 10, 2013
Utility of the bacteriophage RB69 polymerase gp43 as a surrogate enzyme for herpesvirus orthologsNicholas Bennett, Matthias Götte
AIDS Reviews|December 19, 2008
Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibilityMaryam Ehteshami, Matthias Götte
Pageof 13